PEN241220C230000
- 15.30
- 0.000.00%
Penumbra Newsroom
Citi Maintains Penumbra(PEN.US) With Hold Rating, Raises Target Price to $245
Wells Fargo Upgrades Penumbra to Overweight From Equalweight, Price Target Is $190
Wells Fargo Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $275
Positive Outlook for Penumbra: Buy Rating Driven by THUNDER Trial Success and Market Growth Prospects
Penumbra Is Maintained at Buy by Canaccord Genuity
Penumbra Analyst Ratings
CCORF Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $323
Leerink Partners Sticks to Their Buy Rating for Penumbra (PEN)
Penumbra Is Maintained at Buy by BTIG
Penumbra Analyst Ratings
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $270
Cautious Hold Recommendation Amid Uncertainty Following FDA Clearance of Penumbra's Element Vascular Access System
Penumbra's Prospective Growth Amidst Market Dynamics Justifies Hold Rating
Penumbra Is Maintained at Overweight by Piper Sandler
Penumbra Analyst Ratings
Piper Sandler Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $250
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Announces Target Price $240
Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)
Penumbra (PEN) Receives a Buy From BTIG
Penumbra's Strong Q3 2024 Performance and Future Growth Prospects Justify Buy Rating by William Plovanic